According to filings with the U.S. Securities and Exchange Commission, Nektar Therapeutics is raising up to $30,000,000.00 in new funding. Sources indicate that as part of senior management Director, Jeffrey Ajer played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Nektar Therapeutics
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and viral diseases. We leverage Nektars proprietary and proven chemistry platform in the discovery and design of our new drug candidates.

To learn more about Nektar Therapeutics, visit http://www.nektar.com/

Contact:
Jeffrey Ajer, Director
415-482-5300

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.